Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $122.64 Consensus PT from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $124.6818.

KYMR has been the subject of a number of research analyst reports. Truist Financial increased their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Royal Bank Of Canada cut shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their price target for the company from $106.00 to $115.00 in a report on Monday, July 13th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. Bank of America increased their price objective on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, B. Riley Financial lifted their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, June 29th.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 467,878 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the sale, the director directly owned 472,267 shares of the company’s stock, valued at $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,607,813 shares of company stock worth $387,818,004 in the last ninety days. Insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its holdings in shares of Kymera Therapeutics by 169.1% during the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock worth $1,766,000 after buying an additional 14,261 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in Kymera Therapeutics in the 4th quarter valued at $2,610,000. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Eagle Health Investments LP bought a new position in Kymera Therapeutics in the 4th quarter worth $10,606,000. Finally, Maven Securities LTD acquired a new position in Kymera Therapeutics during the 4th quarter worth $1,167,000.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $105.25 on Monday. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The firm’s 50 day simple moving average is $97.90 and its 200-day simple moving average is $87.33. The company has a market cap of $8.66 billion, a P/E ratio of -29.48 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.82) earnings per share. On average, analysts expect that Kymera Therapeutics will post -3.28 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.